Thiery Lebret1, Mathieu Rouanne1, Oleg Hublarov2, Viorel Jinga3, Lidiya Petkova4, Rumen Kotsev5, Ioanel Sinescu6, Pascale Dutailly7. 1. Hôpital Foch - Université Versailles St Quentin en Yvelines, France. 2. Latgalian Urology Centre, Daugavpils, Latvia. 3. 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania. 4. UMHAT Sveta Anna, Varna, Bulgaria. 5. UMHAT G. Stranski, Pleven, Bulgaria. 6. Clinical Hospital Fundeni, Bucharest, Romania. 7. Ipsen Innovation, Les Ulis, France.
Abstract
OBJECTIVES: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1, 3 or 6 months, but in some patients subcutaneous injection may be more appropriate. This study assessed the efficacy and safety profile of the gonadotropin-releasing hormone agonist, triptorelin pamoate, when administered by the subcutaneous route. METHODS: In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later). The co-primary efficacy endpoints were the proportion of patients with a castration level of serum testosterone (<50 ng/dl) after 4 weeks, and of these, those still castrated after 26 weeks. RESULTS: Of the 126 treated patients, 123 [97.6%; 95% confidence interval (CI): 93.2-99.5)] were castrated 4 weeks after the first subcutaneous injection, and 115/119 patients (96.6%; 95% CI: 91.6-99.1) castrated at 4 weeks maintained castration at 26 weeks. Median prostate-specific antigen levels were reduced by 64.2 and 96.0% at 4 and 26 weeks, respectively. The probability of maintaining a testosterone level <20 ng/dl up to 26 weeks was 90.0% (95% CI: 85.0-95.0). The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis). CONCLUSIONS: This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer.
OBJECTIVES:Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1, 3 or 6 months, but in some patients subcutaneous injection may be more appropriate. This study assessed the efficacy and safety profile of the gonadotropin-releasing hormone agonist, triptorelin pamoate, when administered by the subcutaneous route. METHODS: In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later). The co-primary efficacy endpoints were the proportion of patients with a castration level of serum testosterone (<50 ng/dl) after 4 weeks, and of these, those still castrated after 26 weeks. RESULTS: Of the 126 treated patients, 123 [97.6%; 95% confidence interval (CI): 93.2-99.5)] were castrated 4 weeks after the first subcutaneous injection, and 115/119 patients (96.6%; 95% CI: 91.6-99.1) castrated at 4 weeks maintained castration at 26 weeks. Median prostate-specific antigen levels were reduced by 64.2 and 96.0% at 4 and 26 weeks, respectively. The probability of maintaining a testosterone level <20 ng/dl up to 26 weeks was 90.0% (95% CI: 85.0-95.0). The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis). CONCLUSIONS: This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer.
Authors: J M Kuhn; H Abourachid; P Brucher; J C Doutres; J Fretin; A Jaupitre; R Jorest; D Lambert; J Petit; J Pin; J Blumberg; F Dufour-Esquerré Journal: Eur Urol Date: 1997 Impact factor: 20.096
Authors: Luis Martínez-Piñeiro; Jack A Schalken; Patrick Cabri; Pascal Maisonobe; Alexandre de la Taille Journal: BJU Int Date: 2014-04-04 Impact factor: 5.588
Authors: Marjorie C Golekoh; Shengyong Hu; Andrea M Norman; Paul S Horn; Rebecca C Brady; Brenda L Wong Journal: J Child Neurol Date: 2013-03-12 Impact factor: 1.987
Authors: D Fontana; M Mari; A Martinelli; C Boccafoschi; C Magno; M Turriziani; S S Maymone; S Cosciani Cunico; A Zanollo; G Montagna; M Frongia; U Jacobellis Journal: Urol Int Date: 2003 Impact factor: 2.089
Authors: Carlo Alviggi; Alberto Revelli; Paola Anserini; Antonio Ranieri; Luigi Fedele; Ida Strina; Marco Massobrio; Nicola Ragni; Giuseppe De Placido Journal: Reprod Biol Endocrinol Date: 2007-12-04 Impact factor: 5.211